VEGFR2/CD309 Antikörper (AA 20-764)

Produktnummer ABIN969231

Produktdetails anti-VEGFR2/CD309 Antikörper

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Bindungsspezifität: AA 20-764

Reaktivität: Human

Wirt: Maus

Klonalität: Monoklonal

Konjugat: Dieser VEGFR2/CD309 Antikörper ist unkonjugiert

Applikation: Western Blotting (WB), ELISA, Flow Cytometry (FACS), Immunocytochemistry (ICC)

Aufreinigung: purified

Immunogen: Purified recombinant extracellular fragment of human KDR (aa20-764) fused with hIgGFc tag expressed in HEK293 cells.

Klon: 4B4

Isotyp: IgG1

Anwendungsinformationen

Applikationshinweise: ELISA: 1:10000, WB: 1:500 - 1:2000, ICC: 1:200 - 1:1000, FCM: 1:200 - 1:400

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Liquid

Buffer: Ascitic fluid containing 0.03 % sodium azide.

Konservierungsmittel: Sodium azide

Vorsichtsmaßnahmen: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Lagerung: 4 °C/-20 °C

Informationen zur Lagerung: 4°C, -20°C for long term storage

Referenzen für anti-VEGFR2/CD309 Antikörper (ABIN969231)

Takahashi, Yamaguchi, Chida, Shibuya: "A single autophosphorylation site on KDR/Flk-1 is essential for VEGF-A-dependent activation of PLC-gamma and DNA synthesis in vascular endothelial cells." in: The EMBO journal, Vol. 20, Issue 11, pp. 2768-78, (2001) (PubMed).

Details zu VEGFR2/CD309

Target: VEGFR2/CD309 (VEGFR2) (VEGF Receptor 2 (VEGFR2))

Andere Bezeichnung: KDR (VEGFR2 Produkte)

Synonyme: CD309 antikoerper, FLK1 antikoerper, VEGFR antikoerper, VEGFR2 antikoerper, 6130401C07 antikoerper, Flk-1 antikoerper, Flk1 antikoerper, Krd-1 antikoerper, Ly73 antikoerper, VEGFR-2 antikoerper, sVEGFR-2 antikoerper, Vegfr-2 antikoerper, FLK-1 antikoerper, flk-1 antikoerper, vegfr-2 antikoerper, KDR antikoerper, FLK/KDR antikoerper, flk1 antikoerper, flk1b antikoerper, kdrb antikoerper, si:busm1-205d10.1 antikoerper, si:ch211-254j6.1 antikoerper, si:ch211-278f21.4 antikoerper, wu:fc31a09 antikoerper, fk52c05 antikoerper, flk antikoerper, kdr antikoerper, kdra antikoerper, vegfr2 antikoerper, vegfr4 antikoerper, vegr2 antikoerper, wu:fk52c05 antikoerper, kinase insert domain receptor antikoerper, kinase insert domain protein receptor antikoerper, vascular endothelial growth factor receptor kdr-like antikoerper, kinase insert domain receptor (a type III receptor tyrosine kinase) antikoerper, kinase insert domain receptor like antikoerper, KDR antikoerper, Kdr antikoerper, LOC100136647 antikoerper, kdr antikoerper, kdrl antikoerper

Hintergrund:

Description: KDR has also been designated as VEFR-2 (Vascular endothelial growth factor receptor 2), CD309 (cluster of differentiation 309) and Flk1 (fetal liver kinase 1). Vascular endothelial growth factor (VEGF) is a major growth factor for endothelial cells. KDR is one of the two receptors of the VEGF. This receptor, known as kinase insert domain receptor, is a type III receptor tyrosine kinase. It functions as the main mediator of VEGF-induced endothelial proliferation, survival, migration, tubular morphogenesis and sprouting. The signalling and trafficking of this receptor are regulated by multiple factors, including Rab GTPase, P2Y purine nucleotide receptor, integrin alphaVbeta3, T-cell protein tyrosine phosphatase, etc.. Mutations of this gene are implicated in infantile capillary hemangiomas.

Aliases: FLK1, CD309, VEGFR, VEGFR2

Molekulargewicht: 152 kDa

Gen-ID: 3791

HGNC: 3791

Pathways: RTK Signalweg, Glycosaminoglycan Metabolic Process, Signaling Events mediated by VEGFR1 and VEGFR2, Growth Factor Binding, Regulation of long-term Neuronal Synaptic Plasticity, VEGF Signaling